SCHEMBL16398186

SCHEMBL16398186

N#Cc1nn[nH]c1-c1cccc(OCc2cc(C(F)(F)F)ccc2C(F)(F)F)c1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 7/20 0.40
▸ SRD5A2 P31213 1/20 0.40
▸ NR1H3 Q13133 1/20 0.39
▸ SRD5A1 P18405 1/20 0.37
▸ FFAR1 O14842 3/20 0.36
▸ LMNA P02545 1/20 0.35
▸ PKM P14618 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ CTSS P25774 2/20 0.35
▸ CTSK P43235 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ GLA P06280 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ EGFR P00533 1/20 0.35
▸ CYP11B1 P15538 1/20 0.35
▸ PGR P06401 1/20 0.34
▸ AR P10275 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16399733 0.87 SRD5A2 (0.39) NR1H2SRD5A2NR1H3SRD5A1
SCHEMBL16399235 0.85 NR1H2 (0.42) NR1H2SRD5A2NR1H3SRD5A1LMNA
SCHEMBL16399407 0.84 CYP11B1 (0.39) NR1H2NR1H3CTSSKDM4EALDH1A1
SCHEMBL16399312 0.81 ERBB2 (0.43) NR1H2SRD5A2NR1H3SRD5A1CTSS
SCHEMBL18005567 0.81 NR1H2 (0.39) NR1H2SRD5A2NR1H3SRD5A1LMNA
SCHEMBL17969085 0.78 NR1H2 (0.37) NR1H2SRD5A2NR1H3SRD5A1LMNA
SCHEMBL18005872 0.78 SRD5A1 (0.40) NR1H2SRD5A2NR1H3SRD5A1FFAR1
SCHEMBL28876730 0.77 SRD5A2 (0.44) NR1H2SRD5A2NR1H3SRD5A1LMNA
SCHEMBL18004289 0.77 NAAA (0.39) NR1H2NR1H3SRD5A1LMNAPKM
SCHEMBL28320645 0.76 SRD5A2 (0.43) NR1H2SRD5A2NR1H3SRD5A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4570313-A2 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2025-06-18 — — EP claimed
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 — — EP claimed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 — — US claimed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 — — US claimed
EP-4570313-A2 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2025-06-18 — — EP disclosed
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 — — EP disclosed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 — — US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 — — US disclosed
EP-3022199-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2016-05-25 — — EP disclosed
WO-2015008872-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2015-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10626095-B2 Cyanotriazole compounds CS, PC, ACAT1 NR1H2 552/4885SRD5A2 937/4885NR1H3 498/4885
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS CS, PC, ACAT1 NR1H2 552/4885SRD5A2 937/4885NR1H3 498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback